{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:08:09Z","timestamp":1787162889914,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Alexion Pharma G.K., Tokyo, Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12185-022-03287-y","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T21:02:20Z","timestamp":1644526940000},"page":"470-480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7858-278X","authenticated-orcid":false,"given":"Takayuki","family":"Ikezoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyoshi","family":"Noji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirozumi","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Shimono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yonemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuru","family":"Kanakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun\u2011ichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Obara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"3287_CR1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ejh.12543","volume":"95","author":"B Devalet","year":"2015","unstructured":"Devalet B, Mullier F, Chatelain B, Dogn\u00e9 J-M, Chatelain C. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. Eur J Haematol. 2015;95:190\u20138.","journal-title":"Eur J Haematol"},{"key":"3287_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0140-6736(95)12360-1","volume":"348","author":"G Soci\u00e9","year":"1996","unstructured":"Soci\u00e9 G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573\u20137.","journal-title":"Lancet"},{"key":"3287_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","volume":"333","author":"P Hillmen","year":"1995","unstructured":"Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253\u20138.","journal-title":"N Engl J Med"},{"key":"3287_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/01.md.0000126763.68170.46","volume":"83","author":"J-I Nishimura","year":"2004","unstructured":"Nishimura J-I, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193\u2013207.","journal-title":"Medicine (Baltimore)"},{"key":"3287_CR5","first-page":"419","volume-title":"Hematology basic principles and practices","author":"R Brodsky","year":"2005","unstructured":"Brodsky R. Paroxysmal nocturnal hemoglobinuria. In: Hoffman R, et al., editors. Hematology basic principles and practices. 4th ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 419\u201327.","edition":"4"},{"key":"3287_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-T","volume":"73","author":"J Takeda","year":"1993","unstructured":"Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703\u201311.","journal-title":"Cell"},{"key":"3287_CR7","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1182\/blood.V82.4.1192.1192","volume":"82","author":"T Wiedmer","year":"1993","unstructured":"Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993;82:1192\u20136.","journal-title":"Blood"},{"key":"3287_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/asheducation-2016.1.208","volume":"2016","author":"CJ Parker","year":"2016","unstructured":"Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematol Am Soc Hematol Educ Program. 2016;2016:208\u201316.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3287_CR9","unstructured":"Besa EC. Paroxysmal nocturnal hemoglobinuria. Medscape 2020. https:\/\/emedicine.medscape.com\/article\/207468-overview#al. Accessed Sept 15, 2021."},{"key":"3287_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06554.x","volume":"137","author":"A Hill","year":"2007","unstructured":"Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137:181\u201392.","journal-title":"Br J Haematol"},{"key":"3287_CR11","unstructured":"Ministry of Health, Labour and Welfare. Specific Disease Treatment Research Project Research to understand the epidemiological image of untargeted diseases (number of patients, distribution of patients, age, life prognosis, degree of daily life disorders). https:\/\/mhlw-grants.niph.go.jp\/project\/3542\/1. Accessed Sept 15, 2021 (in Japanese)."},{"key":"3287_CR12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s12185-018-2409-3","volume":"107","author":"Y Ueda","year":"2018","unstructured":"Ueda Y, Obara N, Yonemura Y, Noji H, Masuko M, Seki Y, et al. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2018;107:656\u201365.","journal-title":"Int J Hematol"},{"key":"3287_CR13","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","volume":"33","author":"TC Thomas","year":"1996","unstructured":"Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33:1389\u2013401.","journal-title":"Mol Immunol"},{"key":"3287_CR14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Soci\u00e9 G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233\u201343.","journal-title":"N Engl J Med"},{"key":"3287_CR15","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840\u20137.","journal-title":"Blood"},{"key":"3287_CR16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12185-016-2065-4","volume":"104","author":"H Ninomiya","year":"2016","unstructured":"Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2016;104:548\u201358.","journal-title":"Int J Hematol"},{"key":"3287_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1172\/JCI101081","volume":"18","author":"TH Ham","year":"1939","unstructured":"Ham TH, Dingle JH. Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: certain immunological aspects of the hemolytic mechanism with special reference to serum complement. J Clin Investig. 1939;18:657\u201372.","journal-title":"J Clin Investig"},{"key":"3287_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1056\/NEJM196607212750308","volume":"275","author":"RC Hartmann","year":"1966","unstructured":"Hartmann RC, Jenkins DE. The \u201csugar-water\u201d test for paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1966;275:155\u20137.","journal-title":"N Engl J Med"},{"key":"3287_CR19","first-page":"93","volume-title":"Guidelines for the diagnosis and treatment of intractable anemia","author":"J Nishimura","year":"2011","unstructured":"Nishimura J, Kanakura Y. Paroxysmal nocturnal hemoglobinuria. In: Ozawa K, et al., editors. Guidelines for the diagnosis and treatment of intractable anemia. Tokyo: Nankodo; 2011. p. 93\u2013130."},{"key":"3287_CR20","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1182\/blood-2005-02-0564","volume":"106","author":"A Hill","year":"2005","unstructured":"Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:2559\u201365.","journal-title":"Blood"},{"key":"3287_CR21","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031688","volume":"350","author":"P Hillmen","year":"2004","unstructured":"Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552\u20139.","journal-title":"N Engl J Med"},{"key":"3287_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, Muus P, R\u00f6th A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62\u201373.","journal-title":"Br J Haematol"},{"key":"3287_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s12185-013-1404-y","volume":"98","author":"Y Kanakura","year":"2013","unstructured":"Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol. 2013;98:406\u201316.","journal-title":"Int J Hematol"},{"key":"3287_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12185-010-0748-9","volume":"93","author":"Y Kanakura","year":"2011","unstructured":"Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011;93:36\u201346.","journal-title":"Int J Hematol"},{"key":"3287_CR25","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","volume":"117","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117:6786\u201392.","journal-title":"Blood"},{"key":"3287_CR26","doi-asserted-by":"publisher","first-page":"E232","DOI":"10.1002\/ajh.26176","volume":"96","author":"AG Kulasekararaj","year":"2021","unstructured":"Kulasekararaj AG, Brodsky RA, Hill A. Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor. Am J Hematol. 2021;96:E232\u20135.","journal-title":"Am J Hematol"},{"key":"3287_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125215","volume":"10","author":"N Grote Beverborg","year":"2015","unstructured":"Grote Beverborg N, Verweij N, Klip IT, van der Wal HH, Voors AA, van Veldhuisen DJ, et al. Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PLoS\u00a0One. 2015;10:e0125215.","journal-title":"PLoS\u00a0One"},{"key":"3287_CR28","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s10157-009-0197-z","volume":"13","author":"K Kohagura","year":"2009","unstructured":"Kohagura K, Tomiyama N, Kinjo K, Takishita S, Iseki K. Prevalence of anemia according to stage of chronic kidney disease in a large screening cohort of Japanese. Clin Exp Nephrol. 2009;13:614\u201320.","journal-title":"Clin Exp Nephrol"},{"key":"3287_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ajh.21757","volume":"85","author":"P Hillmen","year":"2010","unstructured":"Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85:553\u20139.","journal-title":"Am J Hematol"},{"key":"3287_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","volume":"125","author":"RP de Latour","year":"2015","unstructured":"de Latour RP, Fremeaux-Bacchi V, Porcher R, Xhaard A, Rosain J, Castaneda DC, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125:775\u201383.","journal-title":"Blood"},{"key":"3287_CR31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3324\/haematol.2019.236877","volume":"106","author":"RA Brodsky","year":"2021","unstructured":"Brodsky RA, de Latour RP, Rottinghaus ST, R\u00f6th A, Risitano AM, Weitz IC, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106:230\u20137.","journal-title":"Haematologica"},{"key":"3287_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1159\/000491439","volume":"10","author":"DAC Heesterbeek","year":"2018","unstructured":"Heesterbeek DAC, Angelier ML, Harrison RA, Rooijakkers SHM. Complement and bacterial infections: from molecular mechanisms to therapeutic applications. J Innate Immun. 2018;10:455\u201364.","journal-title":"J Innate Immun"},{"key":"3287_CR33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/21678707.2020.1804858","volume":"8","author":"H Rho","year":"2020","unstructured":"Rho H, Wells RA. Ravulizumab in the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Orphan Drug. 2020;8:257\u201364.","journal-title":"Expert Opin Orphan Drug"},{"key":"3287_CR34","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/bloodadvances.2018020644","volume":"2","author":"A R\u00f6th","year":"2018","unstructured":"R\u00f6th A, Rottinghaus ST, Hill A, Bachman ES, Kim JS, Schrezenmeier H, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies. Blood Adv. 2018;2:2176\u201385.","journal-title":"Blood Adv"},{"key":"3287_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu Z-X, Zhang Y, Patel R, Sun F, Lasaro MA, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS\u00a0One. 2018;13:e0195909.","journal-title":"PLoS\u00a0One"},{"key":"3287_CR36","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, Langermeijer S, Wells R, Ataulfo Gonzalez-Fernandez F, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133:540\u20139.","journal-title":"Blood"},{"key":"3287_CR37","unstructured":"Menactra\u00ae intramuscular injection. Interview form, revised October 2020 (9th edition). https:\/\/www.info.pmda.go.jp\/go\/interview\/1\/780069_6311401A1023_1_009_1F.pdf. Accessed Sept 15, 2021 (in Japanese)."},{"key":"3287_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","volume":"69","author":"SA Mbaeyi","year":"2020","unstructured":"Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69:1\u201341.","journal-title":"MMWR Recomm Rep"},{"key":"3287_CR39","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox LA, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66:734\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3287_CR40","unstructured":"Japanese Society of Hematology. Notes and countermeasures when using Soliris. http:\/\/www.jshem.or.jp\/uploads\/files\/medical\/20180424%20Soliris.pdf. Accessed Sept 15, 2021 (in Japanese)."},{"key":"3287_CR41","unstructured":"Japanese Society of Nephrology. Notes and countermeasures when using Soliris. https:\/\/www.jsn.or.jp\/topics\/notice\/_3430.php. Accessed Sept 15, 2021 (in Japanese)."},{"key":"3287_CR42","unstructured":"Japanese Society of Neurology. Notes and countermeasures when using Soliris. https:\/\/www.neurology-jp.org\/news\/pdf\/news_20180109_01_04.pdf. Accessed Sept 15, 2021 (in Japanese)."},{"key":"3287_CR43","unstructured":"Japan Pediatric Society. Notes and countermeasures when using Soliris. http:\/\/www.jpeds.or.jp\/uploads\/files\/201805Soliris.pdf. Accessed Sept 15, 2021 (in Japanese)."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03287-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03287-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03287-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T15:04:33Z","timestamp":1648652673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03287-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3287"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03287-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasutaka Ueda received support from Alexion in relation to this study; and has received consulting fees from Alexion, Sanofi, Chugai, and Novartis, honoraria\/lecture fees from Alexion Pharma, Sanofi, and Novartis, and participation on data safety monitoring boards or advisory boards for Novartis and Sanofi, unrelated to this study. Kensuke Usuki has received research grants from Astellas, AbbVie, Apellis, SymBio, Daiichi-Sankyo, Novartis, Janssen, Otsuka, Astellas-Amgen-Biopharma, Takeda, Nippon Shinyaku, Bristol-Myers-Squibb, Amgen, Alexion, Incyte, Ono, Kyowa-Kirin, Celgene, Sumitomo-Dainippon, Chugai, Pfizer, Mundi, Yakult, MSD, Gilead, and Nippon-Boehringer-Ingelheim and honoraria\/lecture fees from Novartis, Bristol-Myers-Squibb, Sanofi, Pfizer, AbbVie, Takeda, Ono, Kyowa-Kirin, Astellas, Alexion, Eisai, MSD, Otsuka, Celgene, Daiichi-Sankyo, Nippon Shinyaku, PharmaEssentia, Yakult, SymBio, Alexion, and Chugai, unrelated to this study. Takahisa Matsuda, Hirozumi Akiyama, and Akihiko Shimono are employees of and hold stock in Alexion. Yuji Yonemura and Tatsuya Kawaguchi have received honoraria\/lecture fees from Alexion unrelated to this study. Shigeru Chiba has received honoraria from Janssen, Eisai, Sanofi, Sumitomo-Dainippon, Kyowa-Kirin, Chugai, CSL Bering, Nippon Shinyaku, Meiji-Seika, Novartis, Bristol-Myers-Squib, Astellas, and Otsuka, unrelated to this study. Jun\u2011ichi Nishimura has received consulting fees from Alexion, Roche, Chugai, Novartis, Apellis, BioCryst, and Sanofi, and has patents issued or pending with Roche and Chugai, unrelated to this study. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}